Navigation Links
Syngenta to acquire Pasteuria Bioscience

BASEL, Switzerland, Sept. 19, 2012 /PRNewswire/ --

  • Unique biological technology for nematode control
  • Revolutionary production process
  • First seed treatment for soybean cyst nematode: US launch in 2014
  • Supports integrated offer across key crops

Syngenta announced today that it has agreed to acquire Pasteuria Bioscience, Inc., a US-based biotechnology company. Since 2011 Syngenta and Pasteuria have had an exclusive global technology partnership to develop and commercialize biological products to control plant-parasitic nematodes, using the naturally occurring soil bacteria Pasteuria spp. A revolutionary in-vitro production process will enable the development of cost-effective nematicides with a novel mode of action. The first product will be a seed treatment for soybean cyst nematode to be launched in the USA in 2014.

Under the terms of the agreement, Syngenta will acquire Pasteuria Bioscience for aggregate payments of $86 million, with additional deferred payments of up to $27 million.

Nematodes are a major pest across all crops and the withdrawal of older solutions leaves growers with limited solutions. The acquisition will facilitate the introduction of key products to complement Syngenta's existing chemical nematicide range and to support integrated solutions across a broad variety of crops such as soybean, corn, cereals, sugarbeet and vegetables.

John Atkin, COO of Syngenta, said: "Results from our partnership have shown that Pasteuria provides superior control of nematodes in a wide variety of applications. Pasteuria Bioscience has developed critical knowhow for in-vitro production of Pasteuria, enabling commercial scale manufacturing. This is a further example of our strategy of incorporating biological controls within our integrated offer to growers".

Al Kern, Executive Chairman and President of Pasteuria Bioscience, said: "Pasteuria Bioscience is excited to become part of the Syngenta team. We've been working closely together over the past year and have made significant progress on a number of nematode control products in a variety of crops.  Syngenta recognizes the potential with the Pasteuria platform and can commercialize it in a broad range of products for the global marketplace."

The transaction is expected to close in the fourth quarter of 2012.

Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions.Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements.We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties.Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Syngenta International AG

Media Office
CH-4002 Basel
Tel: +41 61 323 23 23
Fax: +41 61 323 24 24

Media contacts:

Paul Barrett
Switzerland +41 61 323 2323

Paul Minehart
USA + 1 202 737 8913

Analyst/Investor contacts:

Jennifer Gough
Switzerland +41 61 323 5059
USA +1 202 737 6521

Lars Oestergaard
Switzerland +41 61 323 6793
USA +1 202 737 6520

SOURCE Syngenta
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta and Devgen enter insect control research partnership
2. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
3. S.E.D. Labs to be Acquired by Quest Diagnostics
4. Celtaxsys Acquires Clinical Stage Innate Immunity Drug for Inflammation
5. TrovaGene Acquires CLIA - Certified Laboratory
6. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
7. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
8. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
9. inVentiv Health to Acquire SDI Promotional and Medical Audit Businesses From IMS Health
10. GeneThera, Inc. Acquires Applied Genetics, S.A.
11. Amgen to Acquire Micromet
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global Stem Cells Group ... by a world-class team of qualified medical researchers and practitioners, experienced in administering ...
(Date:11/30/2015)... 2015  An interventional radiology technique shows promise for helping ... of a study being presented today at the annual meeting ... (RSNA). --> --> ... interventional radiologists as a way to stop bleeding in emergency ... means of treating obesity is new. Mubin Syed ...
(Date:11/30/2015)... includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ; ... up through cost cuts of priority ... based anywhere in the world will have the right to make, use and distribute ... where licensees based anywhere in the world will have the right to make, use ...
(Date:11/30/2015)... HOLLISTON, Mass. , Nov. 30, 2015 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered ... has received written notification from The NASDAQ Stock ... minimum bid price requirements. The letter noted that ... of HART,s common stock having exceeded $1.00 per ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/19/2015)... YORK , Nov. 19, 2015  Although some ... market is dominated by a few companies, according to ... companies own 51% of the market share of the ... The World Market for Molecular Diagnostic s ... "The market is still controlled by one company ...
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
Breaking Biology News(10 mins):